Needle-free technology, originally developed at the AIBN, has been used to administer a COVID-19 vaccine candidate to successfully protect mice, demonstrating the potential of non-invasive delivery.
Faster-charging and more sustainable batteries with a life up to three times greater than lithium ion are being built with technology developed at AIBN.
A startup company developing technology based on University of Queensland (UQ) research has announced it will partner with the US Government to test its needle-free vaccine delivery technology.
Start-up company Scaled Biolabs Inc is changing the way researchers around the world conduct manual cellular experiments and accelerating discoveries in biology by providing novel devices that enable 1000’s of experiments to occur simultaneously.
A new facility for enzyme formulation and production has been opened, strengthening a collaboration between the Australian Institute for Bioengineering and Nanotechnology and industry partner Bioproton.
Leading American biotechnology company Amyris, Inc. and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland have signed a Memorandum of Understanding to support the development of a Queensland-based biotechnology industry using feedstock from local sugarcane.
